of prolactin in all clinical and physiological situations so far investigated. However, routine establishment of the technique still requires that larger supplies of purified human prolactin are made available.
Prolactin Studies in Normal Subjects
Immunoreactive human prolactin of pituitary origin has been quantitated in serum through its cross-reaction (first reported by Midgley 1971) with ovine prolactin in radioimmunoassay (L'Hermite, Delvoye et al. 1972) . Using this system, serum prolactin levels were found elevated in response to suckling during breast-feeding (L'Hermite, Stavric & Robyn 1972) , in cases of pathological galactorrheea, in response to psychotropic drugs such as sulpiride (L'Hermite, Delvoye et al. 1972) , and during pregnancy .
A circadian periodicity of serum prolactin concentrations hag been described in both men and women (Nokin et al. 1972) , with a nocturnal discharge usually noticeable between 0100 and 0500 hours. In addition, when blood samples were collected every 30 min for a 24 h period additional episodic fluctuations of serum prolactin levels were observed, while the circadian discharge has been found to occur as early as 1900 or as late as 0800 hours (Vanhaelst et al. 1973 ). These observations, together with the very short disappearance half-life of this hormone from blood, make the interpretation of isolated prolactin determinations difficult. On the basis of such daily blood samples it has, however, been possible to demonstrate that prolactin concentrations follow a typical pattern during the normal menstrual cycle: mean levels (n= 18) are higher in the luteal than in the follicular phase and there is a midcycle modest peak (Vekemans et al. 1972).
This suggests that prolactin could be luteotrophic in humans as well as in animals.
Synthetic thyrotrophin-releasing hormone (TRH) induces systematically a release of prolactin as well as of thyrotrophin (TSH), suggesting that TRH could be a physiological prolactinreleasing hormone (l'Hermite, Stavric & Robyn 1972) . But there are various arguments against this hypothesis. TSH and prolactin circadian discharges are completely dissociated in time in some individuals (Vanhaelst et al. 1973) . Insulinic hypoglycemia results in a systematic response of prolactin but not TSH (Copinschi, L'Hermite, Vanhaelst et al. 1972 ). In patients with thyroid diseases, only those athyreotic ones have increased serum basal prolactin levels together with the highest TSH levels encountered (L'Hermite, Bonnyns et al. 1972 ). Hypothyroidism and triiodothyronine treatment result in abolished TSH response to TRH with persistence of the prolactin response (L'Hermite, Bonnyns et al. 1972) .
A battery of tests is available for the investigation of the hypothalamopituitary axis with regard to prolactin secretion; insulinic hypoglycemia and TRH stimulate it, while it is inhibited by L-dopa and 2-Br-a-ergocryptine (CB 154). TRH and CB 154 are likely to act directly on the pituitary while the effects of L-dopa and insulinic hypoglycemia appear to be mediated through the hypothalamus, allowing a disturbance to be located (Copinschi, L'Hermite, Pasteels & Robyn 1972) .
CEstrogens are known to be potent stimulators of prolactin secretion in animals. When postmenopausal women with advanced breast cancer were treated with 3 mg per day ethinylcestradiol orally, initial serum prolactin levels were not significantly different from those of control menopausal women, while cestrogen treatment resulted in always significantly elevated prolactin levels (L'Hermite et al. 1973) . A survey of the problem of the role of prolactin in growth of human breast cancer suggests that a comparison should be made between the presence of receptors for cestrogens, prolactin-dependence and prolactin secretion, and the clinical response to treatment, whether hormonal or not. The level of circulating prolactin is concerned with the induction and growth of mammary tumours in mice and rats (Furth & Clifton 1957 , Muhlbock & Boot 1959 , Pearson et a!. 1969 . Three strains of rats in our laboratories with differing incidences of mammary tumours induced by 7,12 dimethylbenzanthracene (DMBA) were investigated by estimating circulating prolactin at 50 days of age during dicestrus. The strain of rats with the highest incidence of tumours had significantly higher mean circulating prolactin levels than the other two strains (Fig 1) .
Evidence regarding plasma prolactin concentrations in human breast cancer is less exact. We have had experience of two radioimmunoassays, from each strain of dkestrus in three strains ofrat one heterologous (Boyns et al. 1973 , Forrest 1972 and the other homologous. The results of the latter only are reported in this paper. This assay uses a rabbit antihuman amniotic prolactin serum and iodinated human prolactin (kindly supplied by Dr U J Lewis) (Cole & Boyns 1973) .
Untreated Breast Cancer
A single blood sample was taken at the same time each day from 84 patients admitted to hospital not receiving any drug known to stimulate prolactin secretion. Forty-five of these patients had breast cancer, 14 primary and 31 advanced; 39 were hospital controls without breast cancer or other malignant disease. Plasma was stored at -20°C and the assay performed in batches. Mean plasma prolactins in milli ampoules/ml (mAmp/ml) of the MRC standard ampoule (71/222) were 8.3+1.2 for the controls, 10.9± 2.2 for the primary and 8.2±0.9 for the advanced group.
Six additional patients with breast cancer who were on various drugs were also studied. Two were receiving phenothiazines, 2 methyldopa and 1 each stilbcestrol and norethisterone. The circulating prolactin levels ranged from 50 to 100 mAmp/ml.
Effect ofStilbastrol
Prolactin estimations were performed in patients with advanced breast cancer before and at one and three months after the start of therapy with oral stilbeestrol 15 mg daily. In all, plasma prolactin rose during the first month and remained elevated after three months. Two of these patients had an objective remission of their disease. Intravenous injections of stilboestrol diphosphate, 500 mg daily, produced a profound increase in prolactin which was maintained for at least 24 hours.
Pituitary Ablation
Three patients were studied before and following 90yttrium implantation of the pituitary. The plasma prolactin fell within, seventy-two hours and in 2 patients subsequent estimations revealed barely recordable levels. In the third patient significant concentrations of prolactin remained.
It is known that chlorpromazine increases prolactin secretion in man (Turkington 1972) . A single dose of 50 mg chlorpromazine intravenously gave a mean increment of 54.2 mAmp/rnl in the first hour in 5 patients with breast cancer without stimulating a growth hormone response. This test has been compared with a standard insulin in 3 patients one month after 90yttrium implant. In 2 patients both tests were negative; in 1, who subsequently was proved to have an incomplete ablation, reduced but significant response was observed with both.
